Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLOMERULAR DISEASES, CONTAINING GINSENOSIDE RG3 OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2020/145416
Kind Code:
A1
Abstract:
The present invention pertains to a pharmaceutical composition for preventing or treating glomerular diseases, the composition containing ginsenoside Rg3 or a pharmaceutically acceptable salt thereof as an active ingredient. It was found that the ginsenoside Rg3 of the present invention can prevent damage to human podocytes by inhibiting apoptosis and inflammatory response caused by the ER stress of human podocytes. Thus, the ginsenoside Rg3 and a pharmaceutically acceptable salt thereof can be used as an active ingredient of a composition for treating or preventing glomerular diseases.
Inventors:
JEON JIN SEOK (KR)
Application Number:
PCT/KR2019/000217
Publication Date:
July 16, 2020
Filing Date:
January 07, 2019
Export Citation:
Assignee:
JEON JIN SEOK (KR)
International Classes:
A61K31/704; A23L33/125; A61P13/12
Foreign References:
| US20180214466A1 | 2018-08-02 | |||
| KR101948200B1 | 2019-02-14 |
Other References:
"The Korean Society of Nephrology Spring Conference", vol. 1, 2017, article JEON; J. S. EI AL: "Rg3 inhibits puromycin induced apoptosis in human podocyte through suppression of ER stress"
WU. S -B. ET AL.: "Protection of ginsenoside Rg 3 on oxidative stress injury of human glomerular mesangial cells induced by H 2 O 2 and its mechanism", DRUGS & CLINIC, December 2015 (2015-12-01), pages 1437 - 1442, XP055723066
WANG JUAN; CUI CHUN-LI; FU LI; LU QI; YAN QIU; XIE NAN-ZI: "The Effect of Ginsenoside Rg3 on the Biochemical Indicators and Pathological of Diabetic Nephropathy Rats", PROGRESS IN MODERN BIOMEDICINE, vol. 14, no. 36, December 2014 (2014-12-01), pages 7015 - 7018, XP009523759, DOI: 10.13241/j.cnki.pmb.2014.36.004
KANG, K. S. ET AL.: "Therapeutic potential of 20 (S)-ginsenoside Rg3 againststreptozotocin-induced diabetic renal damage in rats", EUROPEAN JOURNAL OF PHARMACOLOGY., vol. 591, 2008, pages 266 - 272, XP023782823
WU. S -B. ET AL.: "Protection of ginsenoside Rg 3 on oxidative stress injury of human glomerular mesangial cells induced by H 2 O 2 and its mechanism", DRUGS & CLINIC, December 2015 (2015-12-01), pages 1437 - 1442, XP055723066
WANG JUAN; CUI CHUN-LI; FU LI; LU QI; YAN QIU; XIE NAN-ZI: "The Effect of Ginsenoside Rg3 on the Biochemical Indicators and Pathological of Diabetic Nephropathy Rats", PROGRESS IN MODERN BIOMEDICINE, vol. 14, no. 36, December 2014 (2014-12-01), pages 7015 - 7018, XP009523759, DOI: 10.13241/j.cnki.pmb.2014.36.004
KANG, K. S. ET AL.: "Therapeutic potential of 20 (S)-ginsenoside Rg3 againststreptozotocin-induced diabetic renal damage in rats", EUROPEAN JOURNAL OF PHARMACOLOGY., vol. 591, 2008, pages 266 - 272, XP023782823
Attorney, Agent or Firm:
PARK, Soo Jo (KR)
Download PDF:
Previous Patent: DRUG DELIVERY PLATFORM USING W/O/W-TYPE TRIOLEIN EMULSION PROMOTIVE OF BLOOD-BRAIN BARRIER OPENING
Next Patent: ROBOT
Next Patent: ROBOT